Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.96−0.22 (-3.06%)
Close on Nov 13, 2026Market cap $459.71MP/E –Yield –
Evolus EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Evolus's EPS for the twelve months ending Sep 30, 2026 was -$0.47. For fiscal 2025 it was -$0.80. The highest annual figure on record is -$0.27 in fiscal 2017.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.80 | – |
| FY2024 | Dec 31, 2024 | -$0.81 | – |
| FY2023 | Dec 31, 2023 | -$1.08 | – |
| FY2022 | Dec 31, 2022 | -$1.33 | – |
| FY2021 | Dec 31, 2021 | -$0.94 | – |
| FY2020 | Dec 31, 2020 | -$4.83 | – |
| FY2019 | Dec 31, 2019 | -$3.19 | – |
| FY2018 | Dec 31, 2018 | -$1.92 | – |
| FY2017 | Dec 31, 2017 | -$0.27 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.19 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.12 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.16 | – |
| Q4 FY2025 | Dec 31, 2025 | $0.00 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.24 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.27 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.30 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.11 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.30 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.18 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.22 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.21 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.30 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.32 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.26 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.23 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.36 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.42 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.31 | -293.8% |
| Q4 FY2021 | Dec 31, 2021 | -$0.33 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.35 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.31 | – |
| Q1 FY2021 | Mar 31, 2021 | $0.16 | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.28 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.34 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.63 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.59 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.47 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.98 | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.37 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.40 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.45 | -266.7% |
| Q3 FY2018 | Sep 30, 2018 | -$0.48 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.69 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.30 | – |
| Q4 FY2017 | Dec 31, 2017 | $0.27 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.16 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.14 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.24 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?